Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma (COEB071X2103)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01854606 |
Recruitment Status
:
Completed
First Posted
: May 15, 2013
Last Update Posted
: May 30, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Study of the safety and efficacy of AEB071 and EVEROLIMUS in patients with CD79-mutant or ABC subtype Diffuse Large B-Cell Lymphoma.
The trial did not progress into Phase II due to the suboptimal tolerability of the combination treatment of sotrastaurin and everolimus in the Phase Ib part of the study. There were no serious safety concerns associated with this combination.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma | Drug: AEB071 Drug: Everolimus | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 31 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-Label, Single-arm, Phase Ib/II Study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR Inhibitor) in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma |
Actual Study Start Date : | December 5, 2013 |
Actual Primary Completion Date : | June 1, 2016 |
Actual Study Completion Date : | June 1, 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: AEB071 and EVEROLIMUS
AEB071 and EVEROLIMUS will be taken together in this open-label non-randomized study
|
Drug: AEB071
a Protein Kinase C Inhibitor
Other Name: sotrastuarin
Drug: Everolimus
mTOR inhibitor
Other Name: RAD001
|
- Phase Ib- Incidence of dose limiting toxicities (DLT) during the first cycle [ Time Frame: 12 months ]Estimate the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of the AEB071and EVEROLIMUS combination therapy in patients with DLBCL.
- Phase II- Overall response rate (ORR) = complete response (CR) + partial response (PR) according to the non-Hodgkin's Lymphoma International Working Group criteria [ Time Frame: 12 months ]Assess the preliminary evidence for anti-tumor activity at RP2D for AEB071 and EVEROLIMUS in patients with a CD79 mutation and those wild-type for the mutation but of the ABC subtype
- Occurrence of Adverse Events (AEs), Serious Adverse Events (SAEs) assessments of clinical laboratory values and vital sign measurements. [ Time Frame: 24 months ]Safety and tolerability of AEB071 and EVEROLIMUS, including acute and chronic toxicities
- Best Overall Response (BOR) [ Time Frame: 24 months ]Evaluate preliminary anti-tumor activity for AE071 and EVEROLIMUS
- Duration of Response (DOR) [ Time Frame: 24 months ]Evaluate preliminary anti-tumor activity for AE071 and EVEROLIMUS
- Progression Free survival (PFS) [ Time Frame: 24 months ]Evaluate preliminary anti-tumor activity for AE071 and EVEROLIMUS
- Overall Survival (OS) [ Time Frame: 24 months ]Evaluate preliminary anti-tumor activity for AE071 and EVEROLIMUS
- Concentration-time profiles of Pharmacokinetics (PK) parameters - Phase Ib [ Time Frame: 24 months ]To characterize the PK profiles of AEB071 and EVEROLIMUS

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female ≥18 years of age.
- Diffuse DLBCL with activating mutations in CD79 (A or B subunits) or ABC-subtype DLBCL (CD79 wildtype or CD79 mutant). DLBCL that arose from transformed indolent lymphoma is allowed.
- Prior treatment and relapse following chemotherapy and autologous bone marrow or stem cell transplant. Patients who are not transplant eligible or who did not respond to chemotherapy may be considered for the study following a single regimen of chemotherapy such as R-CHOP or R-EPOCH. There is no limit to number of prior therapies allowed.
- May be treated with localized radiation as long as measurable or evaluable disease remains at untreated sites.
- WHO performance status of ≤ 2.
- A representative FFPE tumor sample must be available for molecular testing along with a corresponding pathology report. An archival tumor sample may be submitted. However, if not available, a new tumor biopsy obtained for the purpose of this study must be submitted instead.
Exclusion Criteria:
- Treatment with strong inducers or inhibitors (medications and herbal supplements) of cytochrome P450 3A4/5 (CYP3A4/5), or CYP3A4/5 substrates with a QT prolongation risk that cannot be discontinued at least 7 half-lives (or if the half-life is unknown,14 days) prior to study drug treatment.
- Impaired cardiac function or clinically significant cardiac diseases.
- Impairment of GI function or GI disease that could interfere with the absorption of AEB071 or everolimus.
- Severe systemic infections, current or within the two weeks prior to initiation of AEB071.
- Kown history of HIV.
- Poorly controlled diabetes as defined by a fasting serum glucose > 2.0 x ULN.
- Evidence of current CNS involvement.
- Significant symptomatic deterioration of lung function.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01854606
United States, Missouri | |
Washington University School of Medicine Dept of Oncology. | |
Saint Louis, Missouri, United States, 63110 | |
United States, New York | |
Memorial Sloan Kettering Cancer Center Onc. Dept. | |
New York, New York, United States, 10065 | |
United States, Tennessee | |
Sarah Cannon Research Institute Dept of Onc | |
Nashville, Tennessee, United States, 37203 | |
France | |
Novartis Investigative Site | |
Rouen Cedex 1, France, 76038 | |
Germany | |
Novartis Investigative Site | |
Mainz, Germany, 55131 | |
Novartis Investigative Site | |
Muenchen, Germany, 81377 | |
Hong Kong | |
Novartis Investigative Site | |
Hong Kong, Hong Kong | |
Novartis Investigative Site | |
New Territories, Hong Kong | |
Italy | |
Novartis Investigative Site | |
Milano, MI, Italy, 20133 | |
Novartis Investigative Site | |
Milano, MI, Italy, 20141 | |
Korea, Republic of | |
Novartis Investigative Site | |
Seoul, Korea, Korea, Republic of, 03080 | |
Novartis Investigative Site | |
Seoul, Korea, Korea, Republic of, 06351 | |
Netherlands | |
Novartis Investigative Site | |
Rotterdam, Netherlands, 3015 CE | |
Novartis Investigative Site | |
Rotterdam, Netherlands, 3075 EA | |
Taiwan | |
Novartis Investigative Site | |
Taipei, Taiwan, 10002 |
Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Additional Information:
Responsible Party: | Novartis Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT01854606 History of Changes |
Other Study ID Numbers: |
COEB071X2103 |
First Posted: | May 15, 2013 Key Record Dates |
Last Update Posted: | May 30, 2017 |
Last Verified: | May 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes | |
Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Diffuse Large B-Cell Lymphoma, DBCL, AEB071, Everolimus |
Additional relevant MeSH terms:
Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin |
Everolimus Sirolimus Antineoplastic Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Anti-Bacterial Agents Anti-Infective Agents Antibiotics, Antineoplastic Antifungal Agents |